Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI-Powered MRI could spot dangerous brain swelling after stroke

NCT ID NCT07789990

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This study tests whether a high-powered 7T MRI can measure sodium levels in the brain tissue around a bleeding stroke, and whether a drop in sodium predicts worse swelling and disability. Researchers will also use an AI algorithm to create similar sodium maps from standard 3T MRI scans, so the technique could work in hospitals without the ultra-high-field machine. The study enrolls 48 adults who had a bleeding stroke within the past 8 days and follows their recovery for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Synthetic sodium imaging using MRI (7T and 3T) with an AI algorithm to generate sodium concentration maps
What this could lead to
If it works, this could give hospitals a way to predict which stroke patients are at risk of severe brain swelling and poor recovery, using standard MRI machines.
What could go wrong
This is an early imaging study with 48 participants, so the AI-generated maps may not match the 7T scans closely enough, and the link to recovery is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 and 80 years old; * presenting for a first-ever or recurrent symptomatic supratentorial spontaneous ICH within 8 (±2) days after symptoms onset (or last seen well) and confirmed by brain imaging; presumed to be related to small vessel disease. * Patient/legal representative/trusted person who has given written consent to participate in the trial; * Patient covered by social security in France * Patient willing to comply with all study procedures and its duration Exclusion Criteria: * Contra-indication for MRI; * pre-admission disabilities (mRs \> 4); * large ICH of 60 ml or more; * NIH Stroke Scale score \> 20; * item 1a of NIH Stroke Scale (level consciousness) \> 0; * surgical evacuation of ICH, associated intraventricular haemorrhage; ICH due to preceding trauma; ICH suspected to result from an identified intracranial vascular malformation, intracranial venous thrombosis, tumor or haemorrhagic transformation within an infarct. * Epileptic seizure within 48 hours prior to inclusion or anti-epileptic treatment * Patient in the intensive care unit who is intubated and on a ventilator * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral haemorrhage, ich are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.